Palvella Therapeutics (NASDAQ:PVLA) Receives $43.20 Consensus PT from Analysts

Shares of Palvella Therapeutics (NASDAQ:PVLA) have been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $43.50.

A number of brokerages have recently weighed in on PVLA. Jones Trading assumed coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $45.00 price objective on the stock. Stifel Nicolaus assumed coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price objective on the stock. Scotiabank assumed coverage on Palvella Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, February 26th. Finally, Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in shares of Palvella Therapeutics in the 4th quarter valued at $125,000. Toronto Dominion Bank purchased a new position in Palvella Therapeutics in the fourth quarter valued at $159,000. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter worth about $171,000. Cresset Asset Management LLC purchased a new stake in shares of Palvella Therapeutics during the 4th quarter worth about $251,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter valued at about $256,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $27.99 on Tuesday. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27. The stock has a market cap of $314.08 million, a P/E ratio of -2.31 and a beta of 0.54. The stock’s 50 day moving average is $20.54.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.